Comparative Pharmacology
Head-to-head clinical analysis: OMNIPEN AMPICILLIN versus UNIPEN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPEN AMPICILLIN versus UNIPEN IN PLASTIC CONTAINER.
OMNIPEN (AMPICILLIN) vs UNIPEN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and peptidoglycan cross-linking.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and peptidoglycan cross-linking.
250-500 mg orally every 6 hours; 500 mg to 2 g intramuscularly or intravenously every 4-6 hours.
250-500 mg intravenously or intramuscularly every 4-6 hours. Maximum dose 12 g per day.
None Documented
None Documented
Terminal elimination half-life is approximately 1-1.5 hours in adults with normal renal function. In neonates, it may be prolonged to 2-4 hours; in renal impairment, half-life can extend significantly (up to 8-20 hours in severe impairment).
0.5-1 hour (normal renal function); prolonged to 2-5 hours in renal impairment
Renal excretion accounts for approximately 90% of elimination, primarily via tubular secretion and glomerular filtration. Biliary/fecal excretion is minimal, <10%.
Renal: 60-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: minor, <10%
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic